Massive Bio has partnered with patient advocacy organization Sequence Me Now to improve access to cancer clinical trials by connecting genomic testing resources with AI-powered trial matching. Through the collaboration, patients who receive genomic sequencing through Sequence Me Now will be able to seamlessly explore clinical trial opportunities using Massive Bio’s AI platform. The organizations aim to help patients move more efficiently from receiving molecular test results to identifying research studies that match their specific cancer profile.
Massive Bio’s platform uses artificial intelligence to analyze patient medical records, biomarkers and genomic information to identify relevant oncology and hematology clinical trials worldwide. Patients can access personalized trial recommendations through the company’s Patient Connect platform, while physicians can use Trial Relay to identify and manage trial opportunities for their own patients. Under the partnership, Sequence Me Now will direct users to Massive Bio’s trial matching services, while Massive Bio will provide dedicated resources for patients seeking guidance after genomic testing.
The collaboration addresses one of the longstanding challenges in oncology research: connecting eligible patients with appropriate clinical trials. Despite the growing use of precision medicine and genomic sequencing, relatively few cancer patients participate in clinical studies, particularly those living in rural or underserved areas. By combining patient advocacy with AI-driven trial matching, the organizations hope to improve awareness, accelerate recruitment and expand access to investigational therapies tailored to individual genetic profiles.
Click here to read the original news story.
